View Post

Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: oaoa.com Genexine, Inc. (Genexine) and NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the first patient has been dosed in a combination regimen trial to investigate the safety and efficacy of Hyleukin-7™, their T cell amplifier, in combination with Merck’s anti PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with refractory or relapsed triple-negative breast …

View Post

Merck’s Keytruda set to become new standard of care for renal cancer patient population after gaining edge over competitors

In Clinical Trials by Barbara Jacoby

From: globaldata.com Merck & Co Inc’s abstract presentation regarding KEYNOTE-426 trial at ASCO GU 2019 (16 February 2019) has confirmed that Keytruda, an anti-PD-1 therapy, in combination with Pfizer’s Inlyta, a tyrosine kinase inhibitor, can significantly improve clinical outcomes for renal cancer patients. Amrita Gujral, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the …

View Post

Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications

In Clinical Trials by Barbara Jacoby

From: ptcommunity.com Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”) a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, today announced that it has dosed the first patient in its Phase 1/2 clinical trial of EDP1503 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. EDP1503 is an orally delivered monoclonal microbial product candidate being developed for the treatment of …

View Post

Keytruda Performs Well in Latest Lung Cancer Clinical Trials

In In The News by Barbara Jacoby

From: healthline.com The immunotherapy drug has been successful in treating other cancers and the latest trials provide hope for people battling lung cancer. When Edith Pelka was diagnosed with advanced non-small cell lung cancer last summer, the retired New York nurse, yoga instructor, and self-described “straight shooter” thought her life was over. “After the surgeon told me that my tumor …

View Post

Drug Companies to Try a Unified Front Against Cancer

In In The News by Barbara Jacoby

By: ANDREW POLLACK From: nytimes.com Some leading pharmaceutical companies are joining forces in an effort to speed the testing of new types of cancer drugs that harness the body’s immune system to battle tumors. The cooperative effort, announced on Monday, will include Amgen, Celgene and some smaller companies. The effort, known as the National Immunotherapy Coalition, will try to rapidly …

View Post

Huge cancer breakthrough

In In The News by Barbara Jacoby

By: Dan Taylor From: morningticker.com An astonishing breakthrough in cancer treatments could lead to tremendous new treatments. There’s been a tremendous breakthrough in cancer research, and it involves the drug permbrolizumba. Sold in the United States as Keytruda, it has shown an amazing ability to fight lung cancer better than chemotherapty, according to a UPI report. Researchers at the University …

View Post

Tests for new cancer drugs not reliable enough, doctors say

In In The News by Barbara Jacoby

From: reuters.com Drugmakers including Bristol-Myers Squibb Co and Merck & Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Bristol’s Opdivo and Merck’s Keytruda are both therapies designed to block a protein known …

Bristol-Myers, Ono Sue Merck Over Cancer-Drug Patent

In In The News by Barbara Jacoby

By: Peter Loftus From: wsj.com Bristol-Myers Squibb Co. BMY -0.83% and partner Ono Pharmaceutical Co. 4528.TO -0.43% have sued Merck & Co. MRK -0.92% , alleging that its new cancer drug violates their patent for a method of harnessing the body’s immune system to fight cancer. Bristol and Ono filed suit in federal court in Delaware on Thursday, the same …